KS

Kiersten Stead

Managing Partner DCVC Bio: ex-scientist and founder investing in early staged deep tech life sciences

San Francisco, California

VC
Investor

Invests in

Stages:

Seed
Series A

  • Min Investment:

    $5,000,000.00

  • Max Investment:

    $25,000,000.00

  • Target Investment:

    $15,000,000.00

Skills

Cleantech
Investment Banking
Venture Capital
Technology Transfer
Biotechnology
Lifesciences
Agriculture
Start-ups
Molecular Biology
Nanotechnology
Entrepreneurship
Private Equity
Patents
Business Development
Genomics
Medical Devices
R&D
Strategy
Due Diligence
Market Analysis

Education

Investments

Latus Bio

Series A

Total Funding: $54M

Elo Life Systems

Series A

Total Funding: $21M

Totus Medicines

Series B

Total Funding: $110M

Novome Biotechnologies

Series A

Total Funding: $82M

Creyon Bio

Series A

Total Funding: $40M

Plexium

Series B

Total Funding: $140M

GenEdit

Seed

Total Funding: $18M

Pairwise Plants

Series A

Total Funding: $120M

Atomwise

Series A

Total Funding: $170M

FarmLead

Series A

Total Funding: $7M

Work Experience

Nilo Therapeutics

2024

  • Board Member

    2024

Radionetics Oncology

2024

  • Board Member

    2024

Latus Bio

2024

  • Board Member

    2024

Totus Medicines

2024

  • Board Member

    2024

Mycoworks

2019

  • Board Member

    2019

Stemson Therapeutics

2021

  • Board Member

    2021

DCVC Bio

2018

  • Managing Partner

    2018

    Managing Partner DCVC Bio

Keystone Symposia on Molecular & Cellular Biology

2014

  • SAB

    2014

Elo Life Systems

2022 - 2024

  • Board Member

    2022 - 2024

Creyon Bio

2021 - 2024

  • Board Member

    2021 - 2024